Consenso Delphi sobre el manejo de la dislipidemia en pacientes con alteración del metabolismo de la glucosaestudio Diana
- Juan Pedro-Botet 1
- Vivencio Barrios 2
- Vicente Pascual 3
- Juan F. Ascaso 4
- Aleix Cases 5
- Jesús Millán 6
- Adalberto Serrano 7
- Xavier Pintó 8
- 1 Unidad de Lípidos y Riesgo Vascular, Hospital del Mar, Universitat Autònoma de Barcelona
- 2 Servicio de Cardiología, Hospital Universitario Ramón y Cajal
- 3 Centro de Salud Palleter, Castellón
- 4 Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario, Universitat de Valencia
- 5 Servicio de Nefrología, Hospital Clínic de Barcelona
- 6 Cátedra-Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón
- 7 Centro de Salud de Repélega, Portugalete, Vizcaya
- 8 Unidad de Lípidos y Riesgo Vascular, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona
ISSN: 0214-9168, 1578-1879
Datum der Publikation: 2016
Ausgabe: 28
Nummer: 3
Seiten: 132-140
Art: Artikel
Andere Publikationen in: Clínica e investigación en arteriosclerosis
Zusammenfassung
Objectives The aim of the present study was to develop a multidisciplinary consensus based on the Delphi system to establish clinical recommendations for the management of dyslipidaemia when hyperglycaemia is present, and the relevant factors that should be taken into consideration when prescribing and monitoring treatment with statins. Methods The questionnaire developed by the scientific committee included four blocks of questions about dyslipidaemia in patients with impaired glucose metabolism. The results of the first two blocks are presented here: a) management of dyslipidaemia; b) relevant factors that should be taken into consideration when prescribing and monitoring treatment with statins. Results Among the 497 experts who participated in the study, an agreement of over 90% was attained for recommending screening for dyslipidaemia in patients with diabetes or pre-diabetes and/or cardiovascular disease or a family history and/or abdominal obesity and/or hypertension. There was a high degree of agreement that a statin is the lipid-lowering treatment of choice, and that it should be switched when side effects develop. Also, the choice of statin and dose should be made according to baseline LDL cholesterol levels, the target to achieve, and the possible drug-drug interactions. Conclusions The screening of dyslipidaemia is primarily conducted in patients with cardiovascular disease, or any major cardiovascular risk factor. When prescribing a statin, physicians mainly focus on the ability to reduce LDL cholesterol and the risk of drug interactions.